Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

E. Muchtar, Angela Dispenzieri, Shaji K Kumar, F. K. Buadi, Martha Lacy, S. Zeldenrust, S. R. Hayman, N. Leung, Taxiarchis Kourelis, Wilson Gonsalves, R. Chakraborty, Stephen J Russell, David M Dingli, J. A. Lust, Yi Lin, Prashant Kapoor, R. Go, R. A. Kyle, S Vincent Rajkumar, Morie Gertz

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Immunoparesis is an adverse prognostic marker in plasma cell proliferative disorders. Its impact in AL amyloidosis has not been explored in depth. Newly diagnosed AL amyloidosis patients (n=998) were evaluated for immunoparesis by two methods. The first method was qualitative, considering the number of suppressed uninvolved immunoglobulins below the lower limit of normal (LLN) (none, partial, all). The second method was quantitative, assessing the average relative difference (ARD) of the uninvolved immunoglobulins from the LLN. Patients with suppression of all the uninvolved immunoglobulins were less likely to achieve very good partial response (VGPR) or better to first-line treatment (44%) compared with patients with partial suppression (68%) or preserved uninvolved immunoglobulins (64%; P

Original languageEnglish (US)
StateAccepted/In press - Jun 10 2016

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival'. Together they form a unique fingerprint.

Cite this